Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.12 per share a year ago.
Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
3 Top-Ranked Efficient Stocks to Increase Your Portfolio Returns
Invest in companies like Veracyte (VCYT), Steelcase (SCS) and Applied Industrial Technologies (AIT), as they boast higher efficiency levels.
Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High?
The mean of analysts' price targets for Veracyte (VCYT) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.07%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 39.1% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Veracyte (VCYT) Crossed Above the 50-Day Moving Average: What That Means for Investors
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
4 Must-Buy Efficient Stocks to Enrich Your Portfolio
Invest in companies like Veracyte (VCYT), Signet Jewelers (SIG), UMB Financial (UMBF) and NVIDIA (NVDA) to make the most of higher efficiency levels.
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.
Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?
Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Swiss National Bank
Swiss National Bank trimmed its stake in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 143,400 shares of the biotechnology company’s stock after selling 15,800 shares during the period. Swiss National Bank owned about 0.20% of Veracyte worth $3,945,000 at the end of the most recent reporting period. Several other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. raised its holdings in Veracyte by 24.9% during the fourth quarter. Victory Capital Management Inc. now owns 71,259 shares of the biotechnology company’s stock worth $1,960,000 after purchasing an additional 14,219 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Veracyte by 102.2% during the 4th quarter. Russell Investments Group Ltd. now owns 84,808 shares of the biotechnology company’s stock worth $2,333,000 after buying an additional 42,866 shares during the last quarter. Semanteon Capital Management LP purchased a new stake in shares of Veracyte in the 4th quarter worth about $1,238,000. OLD National Bancorp IN acquired a new stake in Veracyte in the 4th quarter valued at about $205,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Veracyte by 3.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,141 shares of the biotechnology company’s stock valued at $554,000 after acquiring an additional 711 shares in the last quarter. Insider Transactions at Veracyte In related news, Director Karin Eastham sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $21.65, for a total value of $216,500.00. Following the completion of the sale, the director now directly owns 33,125 shares in the company, valued at $717,156.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 2.60% of the company’s stock. Analyst Ratings Changes Several analysts have recently commented on the stock. Morgan Stanley lowered their price target on shares of Veracyte from $22.00 to $21.00 and set an “underweight” rating on the stock in a research report on Monday, February 26th. William Blair reissued an “outperform” rating on shares of Veracyte in a research report on Friday, February 23rd. Needham & Company LLC cut their price target on Veracyte from $33.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Finally, The Goldman Sachs Group decreased their price objective on Veracyte from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.50. Get Our Latest Stock Report on Veracyte Veracyte Stock Performance Shares of VCYT opened at $22.88 on Monday. Veracyte, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $30.52. The company has a market capitalization of $1.75 billion, a PE ratio of -24.34 and a beta of 1.65. The stock has a fifty day moving average of $20.92 and a two-hundred day moving average of $23.94. Veracyte (NASDAQ:VCYT – Get Free Report) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.17. Veracyte had a negative return on equity of 1.42% and a negative net margin of 18.16%. The firm had revenue of $96.84 million during the quarter, compared to analyst estimates of $93.35 million. During the same period in the prior year, the firm posted ($0.11) earnings per share. The business’s quarterly revenue was up 17.5% compared to the same quarter last year. As a group, equities research analysts forecast that Veracyte, Inc. will post -0.19 earnings per share for the current fiscal year. Veracyte Company Profile (Free Report) Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.
